Market Cap 811.75M
Revenue (ttm) 719.89M
Net Income (ttm) 98.09M
EPS (ttm) N/A
PE Ratio 7.41
Forward PE 6.21
Profit Margin 13.63%
Debt to Equity Ratio 0.79
Volume 485,100
Avg Vol 594,850
Day's Range N/A - N/A
Shares Out 44.09M
Stochastic %K 91%
Beta 0.97
Analysts Hold
Price Target $23.33

Company Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable f...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 909 980 9484
Address:
11570 6th Street, Rancho Cucamonga, United States
ghfisch
ghfisch May. 22 at 2:08 PM
$AMPH sentiment right now is at 98 out of 100.. I think that's the highest I've ever seen for any stock
1 · Reply
EquityInvest
EquityInvest May. 20 at 2:03 AM
$AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 19 at 11:45 PM
$AMPH Brilliant piece that captures AMPH's situation perfectly. So if you want to update your understanding of AMPH or get to know AMPH better, this is essential reading. https://everyticker.com/quote/AMPH/analysis/amphastar-s-manufacturing-moat-faces-its-moment-of-truth-can-proprietary-pipeline-offset-generic-erosion-nasdaq-amph
0 · Reply
Arcides
Arcides May. 15 at 4:25 PM
$AMPH new 5 years low for this former IBD 50 stock...
0 · Reply
MarketBeat
MarketBeat May. 14 at 6:06 AM
https://marketbeat.com/a/8653243/ $AMPH Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
0 · Reply
Estimize
Estimize May. 12 at 8:00 PM
Wall St is expecting 0.71 EPS for $AMPH Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/amph?chart=historical&metric_name=eps&utm_co
0 · Reply
EquityInvest
EquityInvest May. 8 at 2:43 PM
$AMPH I love this company.  shorting before earnings never fails 🤑😂😂💪
0 · Reply
JRZMike
JRZMike May. 8 at 10:56 AM
$AMPH what a shit show this stock has become
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:30 PM
$AMPH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.14 down -73.58% YoY • Reported revenue of $171.17M up 0.38% YoY
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 23 at 9:39 PM
$AMPH Share Price: $21.01 Contract Selected: Sep 18, 2026 $22.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.15 – $0.18 Potential Upside: 66% ROI Time to Expiration: 147 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on AMPH
Amphastar Pharmaceuticals Slides: FY 2026

May 13, 2026, 6:00 PM EDT - 12 days ago

Amphastar Pharmaceuticals Slides: FY 2026


Amphastar downgraded to Hold from Buy at Needham

2026-05-08T18:05:47.000Z - 17 days ago

Amphastar downgraded to Hold from Buy at Needham


Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 18 days ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2026


Amphastar Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 18 days ago

Amphastar Pharmaceuticals Earnings release: Q1 2026


Amphastar Pharmaceuticals Slides: Q1 2026

May 7, 2026, 5:00 PM EDT - 18 days ago

Amphastar Pharmaceuticals Slides: Q1 2026


Amphastar Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 5:00 PM EDT - 18 days ago

Amphastar Pharmaceuticals Quarterly report: Q1 2026


Amphastar downgraded to Hold from Buy at Jefferies

2026-04-20T20:41:17.000Z - 5 weeks ago

Amphastar downgraded to Hold from Buy at Jefferies


Amphastar Pharmaceuticals Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 6 weeks ago

Amphastar Pharmaceuticals Proxy statement: Proxy filing


Amphastar Pharmaceuticals Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 6 weeks ago

Amphastar Pharmaceuticals Proxy statement: Proxy filing


Amphastar price target lowered to $23 from $30 at Barclays

2026-04-08T09:05:42.000Z - 6 weeks ago

Amphastar price target lowered to $23 from $30 at Barclays


Amphastar price target lowered to $30 from $34 at Wells Fargo

2026-02-27T13:00:20.000Z - 3 months ago

Amphastar price target lowered to $30 from $34 at Wells Fargo


Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2025


Amphastar Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Annual report: Q4 2025


Amphastar Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Earnings release: Q4 2025


Amphastar Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Slides: Q4 2025


Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Feb 24, 2026, 6:00 AM EST - 3 months ago

Amphastar Announces FDA Approval for Ipratropium Bromide HFA


Amphastar price target lowered to $30 from $31 at BofA

2026-01-07T14:30:15.000Z - 4 months ago

Amphastar price target lowered to $30 from $31 at BofA


Amphastar announces FDA approval for teriparatide injection

2025-12-15T11:11:28.000Z - 5 months ago

Amphastar announces FDA approval for teriparatide injection


Amphastar Announces FDA Approval for Teriparatide Injection

Dec 15, 2025, 6:00 AM EST - 5 months ago

Amphastar Announces FDA Approval for Teriparatide Injection


Amphastar initiated with an Equal Weight at Barclays

2025-12-08T21:32:03.000Z - 6 months ago

Amphastar initiated with an Equal Weight at Barclays


Amphastar Pharmaceuticals Slides: FY 2025

Nov 19, 2025, 10:30 AM EST - 6 months ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2025


Amphastar Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Quarterly report: Q3 2025


Amphastar Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Earnings release: Q3 2025


Amphastar Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Slides: Q3 2025


Amphastar price target lowered to $31 from $32 at BofA

2025-10-09T12:35:56.000Z - 8 months ago

Amphastar price target lowered to $31 from $32 at BofA


Amphastar Pharmaceuticals Slides: FY 2025

Sep 3, 2025, 12:45 PM EDT - 9 months ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar price target raised to $32 from $28 at BofA

2025-08-26T10:35:09.000Z - 9 months ago

Amphastar price target raised to $32 from $28 at BofA


Amphastar announced FDA approval of iron sucrose injection

2025-08-12T10:50:52.000Z - 10 months ago

Amphastar announced FDA approval of iron sucrose injection


Needham upgrades Amphastar on valuation post AMP-002 approval

2025-08-12T10:50:46.000Z - 10 months ago

Needham upgrades Amphastar on valuation post AMP-002 approval

VTRS


Amphastar upgraded to Buy from Hold at Needham

2025-08-12T10:45:20.000Z - 10 months ago

Amphastar upgraded to Buy from Hold at Needham


Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

Aug 11, 2025, 6:00 AM EDT - 10 months ago

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP


Amphastar price target lowered to $25 from $30 at Piper Sandler

2025-08-08T11:10:39.000Z - 10 months ago

Amphastar price target lowered to $25 from $30 at Piper Sandler


Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2025


Amphastar Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Amphastar Pharmaceuticals Quarterly report: Q2 2025


Amphastar Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Amphastar Pharmaceuticals Earnings release: Q2 2025


Amphastar Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Amphastar Pharmaceuticals Slides: Q2 2025


Amphastar Pharmaceuticals Slides: FY 2025

Jun 5, 2025, 2:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Slides: FY 2025

May 14, 2025, 4:40 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2025


Amphastar Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Quarterly report: Q1 2025


Amphastar Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q1 2025


Amphastar Pharmaceuticals Slides: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: Q1 2025


Amphastar Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Amphastar Pharmaceuticals Proxy statement: Proxy Filing


Amphastar Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Amphastar Pharmaceuticals Proxy statement: Proxy Filing


Amphastar Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Amphastar Pharmaceuticals Proxy statement: Proxy Filing


Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2024


Amphastar Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Annual report: Q4 2024


Amphastar Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q4 2024


Amphastar Pharmaceuticals Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Slides: Q4 2024


Amphastar Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Slides: FY 2024

Nov 20, 2024, 10:30 AM EST - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2024


Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2024


Amphastar Pharmaceuticals Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Quarterly report: Q3 2024


Amphastar Pharmaceuticals Earnings release: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q3 2024


Amphastar Pharmaceuticals Slides: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Slides: Q3 2024


Amphastar Pharmaceuticals Slides: FY 2024

Sep 5, 2024, 10:15 AM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2024


Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2024


Amphastar Pharmaceuticals Quarterly report: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Quarterly report: Q2 2024


Amphastar Pharmaceuticals Earnings release: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q2 2024


Amphastar Pharmaceuticals Slides: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: Q2 2024


Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts

Jun 18, 2024, 7:20 AM EDT - 2 years ago

Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts

CCRN


ghfisch
ghfisch May. 22 at 2:08 PM
$AMPH sentiment right now is at 98 out of 100.. I think that's the highest I've ever seen for any stock
1 · Reply
EquityInvest
EquityInvest May. 20 at 2:03 AM
$AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 19 at 11:45 PM
$AMPH Brilliant piece that captures AMPH's situation perfectly. So if you want to update your understanding of AMPH or get to know AMPH better, this is essential reading. https://everyticker.com/quote/AMPH/analysis/amphastar-s-manufacturing-moat-faces-its-moment-of-truth-can-proprietary-pipeline-offset-generic-erosion-nasdaq-amph
0 · Reply
Arcides
Arcides May. 15 at 4:25 PM
$AMPH new 5 years low for this former IBD 50 stock...
0 · Reply
MarketBeat
MarketBeat May. 14 at 6:06 AM
https://marketbeat.com/a/8653243/ $AMPH Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
0 · Reply
Estimize
Estimize May. 12 at 8:00 PM
Wall St is expecting 0.71 EPS for $AMPH Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/amph?chart=historical&metric_name=eps&utm_co
0 · Reply
EquityInvest
EquityInvest May. 8 at 2:43 PM
$AMPH I love this company.  shorting before earnings never fails 🤑😂😂💪
0 · Reply
JRZMike
JRZMike May. 8 at 10:56 AM
$AMPH what a shit show this stock has become
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:30 PM
$AMPH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.14 down -73.58% YoY • Reported revenue of $171.17M up 0.38% YoY
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 23 at 9:39 PM
$AMPH Share Price: $21.01 Contract Selected: Sep 18, 2026 $22.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.15 – $0.18 Potential Upside: 66% ROI Time to Expiration: 147 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
briefingcom
briefingcom Apr. 21 at 12:28 PM
$AMPH: Amphastar Pharmaceuticals (-1.1%) downgraded to Hold from Buy at Jefferies, tgt $22 https://www.briefing.com/calendars/updown?Filter=downgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
NewsTrader_perform4nce
NewsTrader_perform4nce Apr. 16 at 1:25 PM
The next Peptide rally at $AMPH?? $HIMS is up 23% since my post last night. Another stock that could also benefit from a peptide boom (so far, the stock has barely reacted) could be $AMPH Amphastar Pharmaceuticals They develop, manufacture, and sell their own medications and peptides. I've added it to my portfolio. Moreover, it's fundamentally quite attractive with a price-to-sales ratio of under 1.5 and a price-to-earnings ratio of 10
0 · Reply
NewsTrader_perform4nce
NewsTrader_perform4nce Apr. 16 at 1:16 PM
Peptides-trade $AMPH .$AMPH is actually the much more obvious peptide pure play compared to $HIMS $AMPH Amphastar is aggressively shifting its portfolio, with plans for proprietary and biosimilar products to represent roughly 85% of its pipeline by 2026, up from 37% in 2021
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 15 at 1:54 PM
$AMPH RSI: 70.11, MACD: -0.1442 Vol: 0.80, MA20: 20.05, MA50: 22.69 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
EquityInvest
EquityInvest Apr. 5 at 8:30 PM
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm - StockStory $AMPH https://stocks.apple.com/AWOhVwXbFT8WELqHZ9VavcQ
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 31 at 8:46 PM
$AMPH Share Price: $19.59 Contract Selected: Sep 18, 2026 $22.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 59% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
stevhoff
stevhoff Mar. 23 at 8:18 PM
$AIRG Friday a 13D was filed by a group of investors: Tim O'Connnell, Haluk Bayraktar and Emre Aciksoz. Tim is with an outfit called Chain Of Lakes Investment Fund which is an activist investment fund, Haluk is head of Baykar Technologies of Turkey( they make the Bayraktar drone for the military which has been used by Ukraine), Emre- don't have anything on the guy other than he's a private investor. These gentlemam have been together on a couple other investments. Back in 2023 they filed a 13D on PCTEL Inc. when the stock was trading around $4. Shortly after Haluk made his filing, the company was acquired by Amphenol($AMPH) for $7/share. Last year the groupd filed a 13D for Lantronix($LTRX) when the stock was trading a little over $2/share, they got a designee to serve on the board of directors: https://www.lantronix.com/newsroom/press-releases/lantronix-enters-into-cooperation-agreement-chain-of-lakes-investment-fund-llc/ The stock rose to over $8 and is still over $5 the group has decreased their stake to below 5%. In the most recent filing for $AIRG, they had this to say: (continued in reply
1 · Reply
Quantumup
Quantumup Mar. 19 at 5:02 PM
Barclays reiterated $XERS Overweight; $9, and said: Current Mkt Cap <$1B Feels Punitive Given $4B Peak Sales. $CORT Torrent Pharmaceuticals Limited/Somerset Therapeutics, LLC $AMPH $ZLDPY $NVO TEVA Barclays added:::LOE Concerns Feel Overblown With a breakout year in 2025 (shares +130%), XERS stock has been volatile in 2026 due primarily to 1) Recorlev LOE concerns and 2) macro volatility. While we have less visibility into the macro, we think the LOE concerns are overblown and came away from our Miami conf with increased conviction.
1 · Reply
Prodify2003
Prodify2003 Mar. 13 at 8:01 PM
$AMPH I work here and it’s a shit show . Everything is so outdated here
0 · Reply
EquityInvest
EquityInvest Mar. 6 at 3:05 PM
$AMPH 🤣🤣🤣
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 28 at 1:53 AM
$AMPH Share Price: $20.26 Contract Selected: Sep 18, 2026 $30 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.31 – $0.38 Potential Upside: 73% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Arcides
Arcides Feb. 27 at 9:06 PM
$AMPH new52 weeks low with the highest dailyvolume in a year, totally crushed today...
0 · Reply